To evaluate the efficacy and safety of recombinant human serum albumin /granulocyte colonystimulating factor (rHSA/G-CSF) in breast cancer following receipt of cytotoxic agents. The prospective randomized controlled trials demonstrated that rHSA/G-CSF was efficacious and welltolerated with an approachable frequency and expense of application for prophylactic management of agranulocytosis. |